This study looks at how a drug called **Dalcetrapib** affects heart health in people with a special genetic makeup who recently had an Acute Coronary Syndrome (ACS) event, which means a sudden heart problem. Some people will get a placebo, which is a fake pill with no medicine, to compare results. The study is "double-blind," meaning neither the doctors nor the participants know who gets the real drug or the placebo.

To join, you must be 45 or older and have a specific genetic type known as **AA genotype**. You should also be stable without severe heart symptoms for at least a week. The study will last until 200 people have a main heart event. Visits will be virtual every 3 months if possible, or in a clinic.

• **Length**: Lasts until 200 events occur.
• **Visits**: Every 3 months, mostly virtual.
• **Compensation**: Not specified.

Pregnant women or those with certain health issues, like severe heart failure or high blood pressure, cannot join. No recent participation in other drug studies is allowed.